Cargando…
Biopharmaceutical benchmarks 2022
Monoclonal antibodies as a group continue to lead biopharmaceuticals in numbers of approvals and sales, although COVID-19 vaccines shot to the top of the list of highest-grossing individual products.
Autores principales: | Walsh, Gary, Walsh, Eithne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735008/ https://www.ncbi.nlm.nih.gov/pubmed/36471135 http://dx.doi.org/10.1038/s41587-022-01582-x |
Ejemplares similares
-
Biopharmaceuticals : biochemistry and biotechnology
por: Walsh, Gary
Publicado: (2003) -
Biopharmaceuticals : biochemistry and biotechnology /
por: Walsh, Gary
Publicado: (1998) -
Hagit Shatkay-Reshef 1965–2022
por: Arighi, Cecilia N
Publicado: (2022) -
Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D
por: Farid, Suzanne S., et al.
Publicado: (2020) -
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
por: Snowden, John A., et al.
Publicado: (2022)